O	0	4	Late
O	5	14	radiation
O	15	23	toxicity
O	24	29	after
B-intervention	30	44	intraoperative
I-intervention	45	57	radiotherapy
I-intervention	58	59	(
I-intervention	59	63	IORT
I-intervention	63	64	)
O	65	68	for
O	69	75	breast
O	76	82	cancer
O	82	83	:
O	84	91	results
O	92	96	from
O	97	100	the
O	101	111	randomized
O	112	117	phase
O	118	121	III
O	122	127	trial
O	128	134	TARGIT
O	135	136	A
O	136	137	.

O	138	141	The
O	142	152	randomized
O	153	158	phase
O	159	162	III
O	163	168	trial
O	169	175	TARGIT
O	176	177	A
O	178	184	showed
O	185	188	non
O	188	189	-
O	189	200	inferiority
O	201	210	regarding
O	211	216	local
O	217	224	control
O	225	230	after
O	231	245	intraoperative
O	246	258	radiotherapy
O	259	260	(
O	260	264	IORT
O	265	267	20
O	268	270	Gy
O	271	276	which
O	277	280	was
O	281	289	followed
O	290	292	by
O	293	298	whole
O	299	305	breast
O	306	318	radiotherapy
O	319	320	(
O	320	324	WBRT
O	324	325	)
O	326	328	in
O	329	337	patients
O	338	342	with
O	343	347	risk
O	348	355	factors
O	356	360	only
O	360	361	)
O	362	364	in
O	365	375	comparison
O	376	378	to
O	379	387	standard
O	388	392	WBRT
O	393	394	(
O	394	396	50
O	396	397	-
O	397	399	56
O	400	402	Gy
O	402	403	)
O	404	409	after
O	410	416	breast
O	416	417	-
O	417	427	conserving
O	428	435	surgery
O	436	438	in
O	439	447	selected
O	448	456	patients
O	456	457	.

O	458	462	This
O	463	465	is
O	466	469	the
O	470	475	first
O	476	484	analysis
O	485	487	of
O	488	492	long
O	492	493	-
O	493	497	term
O	498	508	toxicities
O	509	511	in
O	512	515	the
O	516	523	setting
O	524	526	of
O	527	533	TARGIT
O	533	534	.

O	535	542	Between
O	543	545	02
O	545	546	/
O	546	550	2002
O	551	554	and
O	555	557	12
O	557	558	/
O	558	562	2008
O	562	563	,
B-total-participants	564	567	305
O	568	576	patients
O	577	581	were
O	582	589	treated
O	590	596	within
O	597	603	TARGIT
O	604	605	A
O	606	607	(
O	607	610	Arm
O	611	612	A
O	612	613	:
O	614	615	n
O	616	617	=
B-intervention-participants	618	620	34
O	621	625	IORT
O	625	626	,
O	627	628	n
O	629	630	=
B-intervention-participants	631	633	20
O	634	638	IORT
O	639	640	+
O	641	645	WBRT
O	646	649	for
O	650	654	risk
O	655	662	factors
O	662	663	;
O	664	667	Arm
O	668	669	B
O	670	674	WBRT
O	674	675	:
O	676	677	n
O	678	679	=
B-intervention-participants	680	682	55
O	682	683	)
O	684	686	or
O	687	695	received
O	696	700	IORT
O	701	703	as
O	704	705	a
O	706	713	planned
O	714	719	boost
O	720	721	(
B-control	721	728	control
I-control	729	734	group
O	734	735	:
O	736	737	n
O	738	739	=
B-control-participants	740	743	196
O	743	744	)
O	745	747	at
O	748	749	a
O	750	756	single
O	757	763	center
O	763	764	.

O	765	773	Toxicity
O	774	777	was
O	778	786	assessed
O	787	796	according
O	797	799	to
O	800	803	the
O	804	808	LENT
O	809	813	SOMA
O	814	820	scales
O	820	821	.

O	822	824	No
O	825	836	significant
O	837	848	differences
O	849	853	were
O	854	858	seen
O	859	866	between
O	867	870	Arm
O	871	872	A
O	873	876	and
O	877	880	Arm
O	881	882	B
O	883	892	regarding
B-outcome	893	901	fibrosis
I-outcome	901	902	,
I-outcome	903	909	breast
I-outcome	910	915	edema
I-outcome	915	916	,
I-outcome	917	927	retraction
I-outcome	927	928	,
I-outcome	929	939	ulceration
I-outcome	939	940	,
I-outcome	941	951	lymphedema
I-outcome	951	952	,
I-outcome	953	970	hyperpigmentation
I-outcome	970	971	,
I-outcome	972	975	and
I-outcome	976	980	pain
O	980	981	.

O	982	985	Arm
O	986	987	A
O	988	991	had
O	992	1005	significantly
O	1006	1010	less
B-outcome	1011	1025	telangiectases
O	1026	1034	compared
O	1035	1037	to
O	1038	1041	Arm
O	1042	1043	B
O	1044	1045	(
O	1045	1046	p
O	1047	1048	=
O	1049	1050	0
O	1050	1051	.
O	1051	1054	049
O	1054	1055	)
O	1055	1056	.

O	1057	1059	In
O	1060	1063	the
O	1064	1075	subanalysis
O	1076	1077	(
O	1077	1080	Arm
O	1081	1082	A
O	1083	1087	IORT
O	1088	1090	vs
O	1090	1091	.
O	1092	1095	Arm
O	1096	1097	A
O	1098	1102	IORT
O	1103	1104	+
O	1105	1109	WBRT
O	1110	1112	vs
O	1112	1113	.
O	1114	1117	Arm
O	1118	1119	B
O	1119	1120	)
O	1120	1121	,
B-outcome	1122	1130	fibrosis
O	1131	1134	had
O	1135	1136	a
O	1137	1147	cumulative
O	1148	1152	rate
O	1153	1155	of
B-iv-bin-percent	1156	1157	5
I-iv-bin-percent	1157	1158	.
I-iv-bin-percent	1158	1159	9
O	1160	1166	versus
B-iv-bin-percent	1167	1169	37
I-iv-bin-percent	1169	1170	.
I-iv-bin-percent	1170	1171	5
O	1172	1178	versus
B-iv-bin-percent	1179	1181	18
I-iv-bin-percent	1181	1182	.
I-iv-bin-percent	1182	1183	4
I-iv-bin-percent	1184	1185	%
O	1185	1186	,
O	1187	1199	respectively
O	1200	1201	(
B-cv-bin-percent	1201	1203	38
I-cv-bin-percent	1203	1204	.
I-cv-bin-percent	1204	1205	2
I-cv-bin-percent	1206	1207	%
O	1208	1212	IORT
O	1213	1218	boost
O	1219	1226	control
O	1227	1232	group
O	1232	1233	)
O	1233	1234	,
B-outcome	1235	1237	at
I-outcome	1238	1239	3
I-outcome	1240	1245	years
O	1245	1246	.

O	1247	1249	No
B-outcome	1250	1264	telangiectases
O	1265	1269	were
O	1270	1274	seen
O	1275	1280	after
O	1281	1285	IORT
O	1286	1291	alone
O	1292	1293	(
B-iv-bin-percent	1293	1294	0
I-iv-bin-percent	1295	1296	%
O	1297	1300	Arm
O	1301	1302	A
O	1303	1307	IORT
O	1308	1310	vs
O	1310	1311	.
B-iv-bin-percent	1312	1314	17
I-iv-bin-percent	1314	1315	.
I-iv-bin-percent	1315	1316	5
I-iv-bin-percent	1317	1318	%
O	1319	1322	Arm
O	1323	1324	A
O	1325	1329	IORT
O	1330	1331	+
O	1332	1336	WBRT
O	1337	1339	vs
O	1339	1340	.
B-iv-bin-percent	1341	1343	17
I-iv-bin-percent	1343	1344	.
I-iv-bin-percent	1344	1345	7
I-iv-bin-percent	1346	1347	%
O	1348	1351	Arm
O	1352	1353	B
O	1353	1354	)
O	1354	1355	.

O	1356	1359	The
O	1360	1366	hazard
O	1367	1372	ratio
O	1373	1375	of
B-outcome	1376	1382	higher
I-outcome	1383	1388	grade
I-outcome	1389	1397	toxicity
O	1398	1400	as
O	1401	1406	first
O	1407	1412	event
O	1413	1416	was
O	1417	1418	0
O	1418	1419	.
O	1419	1421	46
O	1422	1423	(
O	1423	1425	95
O	1426	1427	%
O	1428	1430	CI
O	1430	1431	,
O	1432	1433	0
O	1433	1434	.
O	1434	1436	26
O	1436	1437	-
O	1437	1438	0
O	1438	1439	.
O	1439	1441	83
O	1441	1442	)
O	1443	1446	for
O	1447	1450	Arm
O	1451	1452	A
O	1453	1457	IORT
O	1458	1460	as
O	1461	1469	compared
O	1470	1472	to
O	1473	1476	Arm
O	1477	1478	B
O	1479	1480	(
O	1480	1481	p
O	1482	1483	=
O	1484	1485	0
O	1485	1486	.
O	1486	1489	010
O	1489	1490	)
O	1490	1491	.

O	1492	1494	No
B-outcome	1495	1506	recurrences
O	1507	1511	were
O	1512	1516	seen
O	1517	1522	after
O	1523	1524	a
O	1525	1531	median
O	1532	1538	follow
O	1538	1539	-
O	1539	1541	up
O	1542	1544	of
B-iv-cont-median	1545	1547	40
I-iv-cont-median	1548	1554	months
O	1555	1556	(
O	1556	1559	Arm
O	1560	1561	A
O	1561	1562	)
O	1563	1566	and
B-cv-cont-median	1567	1569	42
I-cv-cont-median	1570	1576	months
O	1577	1578	(
O	1578	1581	Arm
O	1582	1583	B
O	1583	1584	)
O	1584	1585	.

O	1586	1590	With
O	1591	1594	its
O	1595	1599	very
O	1600	1603	low
O	1604	1611	chronic
O	1612	1616	skin
O	1617	1625	toxicity
O	1626	1631	rates
O	1632	1635	and
O	1636	1647	outstanding
O	1648	1652	long
O	1652	1653	-
O	1653	1657	term
O	1658	1665	results
O	1666	1675	regarding
O	1676	1684	toxicity
O	1685	1688	and
O	1689	1694	local
O	1695	1702	control
O	1702	1703	,
O	1704	1708	IORT
O	1709	1713	with
O	1714	1716	50
O	1717	1719	kV
O	1720	1721	X
O	1721	1722	-
O	1722	1726	rays
O	1727	1729	is
O	1730	1731	a
O	1732	1736	safe
O	1737	1740	and
O	1741	1750	effective
O	1751	1757	method
O	1758	1761	for
O	1762	1771	treatment
O	1772	1774	of
O	1775	1783	selected
O	1784	1790	breast
O	1791	1797	cancer
O	1798	1806	patients
O	1806	1807	.
